인쇄하기
취소

Celltrion reveals Phase 3 clinical trial result of Herzuma at world’s largest oncology conference

Published: 2017-06-08 13:20:44
Updated: 2017-06-08 13:20:44

Celltrion announced a result of the clinical trials of Herzuma(project name: CT-P6), an antibody biosimilar for the treatment of breast cancer, and Truxima(project name: CT-P10), a biosimilar for the treatment of hematological malignancy, at the American Society of Clinical Oncology in Chicago on the 4th.

At the event, the result of the Phase 3 clinical trial of comparing Herzuma to the origin...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.